CRP and type 2 diabetes mellitus: A meta-analysis of randomized controlled trials has demonstrated that effective anti-inflammatory therapy can substantially decrease the concentrations fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), and C-reactive protein (CRP) among patients with T2D, and that individuals with new-onset type 2 diabetes can gain more benefits from this therapeutic approach (9).